- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01336049
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
April 14, 2011 updated by: Peking University
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
Nimotuzumab, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in some studies with head-neck cancers.
Advanced esophageal carcinoma have poor prognosis and majority of patients resistant to chemotherapy in China.
In the investigators phase II clinical trial proceeded before,the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal carcinoma.
The investigators then initiated a prospective phase II clinical trial with Nimotuzumabplus paclitaxel/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Xiaodong Zhang
-
Contact:
- xiaodong zhang, MD
- Phone Number: 86-10-88196175
- Email: zxd0829@yahoo.com.cn
-
Principal Investigator:
- xiaodong zhang, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Having signed informed consent
- Age 18 to 75 years old
- Histologically confirmed esophageal squamous carcinoma, Unresectable recurrent or metastatic disease,no prior palliative chemotherapy; No prior radiotherapy except radiotherapy at non-target lesion of the study more than 3 months,recurrence from last adjuvant chemotherapy or adjuvant radiotherapy should be longer than 6 months; no prior treatment of paclitaxel as adjuvant chemotherapy, total dose of cisplatin is less than 300mg/m2 if used in adjuvant chemotherapy
- Sex is not limited
- Measurable disease according to the RECIST criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 15 days before enrollment)
- Karnofsky performance status ≥80
- Life expectancy of ≥ 3 month
- WBC > 4,000/mm3, absolute neutrophil count ≥2000/mm3, platelet > 100,000/mm3, Hb > 10g/dl(within 14 days before enrollment),ALT and AST < 2.5 times ULN (≤5 times ULN in patients with liver metastases),Bilirubin level < 1.0 times ULN,Serum AKP < 2.5 times ULN,Serum creatinine < 1.0 times ULN
- No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever > 38℃;
- Normal ECG and heart function
- Fertile patients must use effective contraception
- Good compliance
Exclusion Criteria:
- Previous treatment of palliative chemotherapy or recurrence less than 6 months from time of last adjuvant chemo-/radiotherapy
- Known hypersensitivity to Nimotuzumab,Paclitaxel,Cisplatin
- Only with Brain or bone metastasis
- Tumor with length ≥ 10cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung
- No measurable lesions, eg. pleural fluid and ascites
- Suffer from severe heart disease or disease with other important organs
- Chronic diarrhea or renal dysfunction
- Pregnancy or lactation period
- Other previous malignancy within 5 year, except non-melanoma skin cancer
- Chronic diarrhea
- Mentally abnormal or disable cognition,including CNS metastasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nimotuzumab
|
Nimotuzumab 200mg/week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate
Time Frame: 6 weeks
|
CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival of all participants
Time Frame: 2 years
|
OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
|
2 years
|
progression free survival
Time Frame: 1 year
|
the follow-up visit of PFS will be performed every 2 cycles
|
1 year
|
adverse events
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week
|
any adverse event will be record on CRF for safety control
|
participants will be followed for the duration of hospital stay, an expected average of 1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Anticipated)
December 1, 2011
Study Registration Dates
First Submitted
March 29, 2011
First Submitted That Met QC Criteria
April 14, 2011
First Posted (Estimate)
April 15, 2011
Study Record Updates
Last Update Posted (Estimate)
April 15, 2011
Last Update Submitted That Met QC Criteria
April 14, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Neoplasms, Squamous Cell
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Nimotuzumab
Other Study ID Numbers
- N+TP-AEC3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Cancer
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
RenJi HospitalRecruitingAdvanced Esophageal Squamous Cell CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownAdvanced Esophageal Squamous Cell CancerChina
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
Peking UniversityUnknownChemotherapy Effect | Esophageal Cancer, Squamous Cell | Cetuximab EffectChina
-
Shanghai Junshi Bioscience Co., Ltd.CompletedAdvanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic ChemotherapyChina
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruiting
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
Peking Union Medical College HospitalNot yet recruitingAnlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
-
Sun Yat-sen UniversityActive, not recruiting
Clinical Trials on Nimotuzumab
-
Cancer Institute and Hospital, Chinese Academy...UnknownGastric Cancer | Concurrent ChemoradiotherapyChina
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Unknown
-
Peking Union Medical College HospitalNot yet recruiting
-
Peking UniversityUnknownEsophageal Squamous Cell CancerChina
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang Goethe... and other collaboratorsCompleted
-
University of SaskatchewanRecruitingColorectal Cancer | Lung CancerCanada
-
YM BioSciencesCIMYM BioSciencesTerminatedMetastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Canada, Cuba, Pakistan
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Wuerzburg; Children's Medical... and other collaboratorsCompleted
-
Cancer Institute and Hospital, Chinese Academy...RecruitingEsophageal Cancer | Chemotherapy | Immunotherapy | Chemoradiotherapy | NimotuzumabChina
-
Health Science Center of Xi'an Jiaotong UniversityRecruiting